LAVA Therapeutics N.V. (LVTX)

Market Cap	48.39M
Revenue (ttm)	7.40M
Net Income (ttm)	-24.18M
Shares Out	26.30M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,717
Open	1.850
Previous Close	1.890
Day's Range	1.800 - 1.970
52-Week Range	1.317 - 6.470
Beta	0.48
Analysts	Strong Buy
Price Target	6.00 (+226.09%)
Earnings Date	Nov 18, 2024

About LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2021
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: LVTX
• Website: https://www.lavatherapeutics.com

Financial Performance

In 2023, LAVA Therapeutics's revenue was $6.77 million, a decrease of -65.09% compared to the previous year's $19.39 million. Losses were -$41.97 million, 31.6% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for LVTX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 226.09% from the latest price.

Price Target

$6.0

(226.09% upside)

Analyst Consensus: Strong Buy